Our Faculty
Jonathan M. Meyer, M.D.
Publications of Jonathan M. Meyer, M.D.
Managing Some Unique Nonhematologic Adverse Effects of Clozapine
1.25 CMEs
In this presentation, Dr. Jonathan Meyer discusses the management of nonhematologic adverse effects of clozapine, such as sialorrhea, constipation, tachycardia, and seizures. He provides valuable information for the assessment of these side effects and gives a thorough explanation of how to manage each of them. At the end of the presentation, he provides a clinical vignette to elucidate the management of clozapine-induced constipation.
Use of Psychotropics in Patients With Hepatic Issues – Interview
0.50 CMEs
In this interview, Dr. Jonathan Meyer discusses practical considerations when prescribing psychotropic medications for patients with hepatic issues. He emphasizes the use of the Child-Pugh Score in determining how hepatic impairment can affect drug metabolism and the need for subsequent dosing adjustments. He also clarifies dosing considerations for specific medications, such as clozapine, olanzapine, and valproate, in the context of patients with hepatic issues.
Use of Psychotropics in Patients With Hepatic Issues
1.00 CMEs
In this presentation, Dr. Jonathan Meyer discusses whether it is safe to use psychotropics in patients with hepatic issues, such as steatosis, cirrhosis, and hepatitis C. He also guides clinicians on assessing liver function and the utility and interpretation of the Child-Pugh scale. Finally, he presents a clinical vignette to assess valproate safety in patients with hepatitis C and when to adjust the dose.
Modern Use of MAOIs – Interview
0.50 CMEs
In this interview, Dr. Jonathan Meyer discusses how MAOIs remain a useful and evidence-based option in several clinical scenarios. He describes the liability issues and how to manage realistic dietary restrictions. Dr. Meyer also evaluates their advantages over more invasive treatments and some augmentation strategies that are available for MAOIs.
Modern Use of Antipsychotic Plasma Levels – Interview
0.50 CMEs
This interview with Dr. Jonathan Meyer is focused on the modern use of antipsychotic plasma levels in clinical practice. The relationship between dopamine D2 occupancy and antipsychotic response and what happens when D2 occupancy exceeds 80% are discussed.
Modern Use of MAOIs
0.75 CMEs
In this presentation, Dr. Jonathan Meyer gives an overview of MAOIs regarding their pharmacology, dietary restrictions, and drug interactions. He also explains how to initiate treatment with MAOIs and how to use augmentation strategies when necessary.
Managing Nonhematological Adverse Effects of Clozapine – Interview
0.50 CMEs
This interview with Dr. Jonathan Meyer covers a diverse range of topics relating to nonhematological adverse effects of clozapine. You will hear tips on improving compliance with clozapine use and find out just how significant pneumonia risk is with sialorrhea. Also, Dr. Meyer touches upon lubiprostone and linaclotide for constipation and prophylactic metformin to counteract clozapine-induced metabolic syndrome.
Antipsychotic Blood Levels
1.00 CMEs
In this presentation, Dr. Jonathan Meyer discusses the benefits and limitations of cross-sectional plasma antipsychotic levels to guide treatment decisions. The relationship between D2 occupancy and antipsychotic plasma levels are explored, as is how to combine information from antipsychotic plasma levels with the clinical picture to determine an appropriate course of action.
Managing the Nonhematological Adverse Effects of Clozapine
0.75 CMEs
This presentation provides practical information on the management of nonhematological adverse effects of clozapine, such as sialorrhea, constipation, orthostasis, fever, tachycardia, myocarditis and cardiomyopathy, metabolic effects, sedation, and seizures.